CRYSTAL FLORES-ALAMO: Open Payments
NPI 1932889318 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$926 in 49 payments from 20 companies in 2025. Trend: 2023 $67 · 2024 $499 · 2025 $926
Food & beverage: $926
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 10 | $149 |
| Novo Nordisk Inc | 7 | $133 |
| Lilly USA, LLC | 2 | $124 |
| Axsome Therapeutics, Inc. | 5 | $73 |
| Novartis Pharmaceuticals Corporation | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| ABBVIE INC. | 3 | $47 |
| PFIZER INC. | 2 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Exact Sciences Corporation | 2 | $39 |
Products named: FANAPT, ZEPBOUND, Ozempic, LEQVIO, REXULTI, CAPLYTA, Auvelity, Rybelsus.
Industry payments across ID — which companies pay providers there.
